Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2+/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49-MedSci.cn

Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2+/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49

Pernot, S; Pellerin, O; Mineur, L; Monterymard, C; Smith, D; Lapuyade, B; Gallois, C; Tougeron, D; Thirot-Bidault, A; Audemar, F; Simon, M; Lecaille, C; Louafi, S; Lepage, C; Ducreux, M; Taieb, J; Akouz, FK; De Baere, T

Pernot, S (通讯作者)，Inst Bergonie, Dept Med Oncol, 229 Cours Argonne, F-33076 Bordeaux, France.

Abstract

Introduction: In patients with unresectable liver metastases from colorectal cancer (CRCLM), systemic doublet or triplet chemotherapy and targeted the......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2+/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49

科室

工具

服务